PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27713373-6	2010	EPHX1 polymorphisms may be associated with the pharmacokinetics of carbamazepine and the risk of phenytoin-induced congenital malformations.	Phenytoin	97-106	epoxide hydrolase 1	Homo sapiens	0-5	
19364907-1	2009	Microsomal epoxide hydrolase (EPHX1) biotransforms epoxide derivatives of pharmaceuticals, including metabolites of certain antiepileptic medications, such as phenytoin and carbamazepine, and many environmental epoxides, such as those derived from butadiene, benzene, and carcinogenic polyaromatic hydrocarbons.	Phenytoin	159-168	epoxide hydrolase 1	Homo sapiens	0-28	
19952982-0	2010	Maternal EPHX1 polymorphisms and risk of phenytoin-induced congenital malformations.	Phenytoin	41-50	epoxide hydrolase 1	Homo sapiens	9-14	
19952982-2	2010	The goal of this study was to assess the effect of maternal genotype of functional polymorphisms in two genes involved in phenytoin metabolism, CYP2C9 (R144C, I395L) and EPHX1 (Y113H, H139R), on the presence of major craniofacial abnormalities (CFAs) in the child.	Phenytoin	122-131	epoxide hydrolase 1	Homo sapiens	170-175	
19952982-6	2010	In a logistic regression model adjusted for history of phenytoin use during the first trimester and maternal epilepsy (N=157 pregnancies), the maternal EPHX1 113 H [per rare allele odds ratio (OR): 2.43, 95% confidence interval (CI): 1.16-5.10, P=0.02] and 139 R (per rare allele OR: 2.33, 95% CI: 1.09-5.00, P=0.03) alleles were associated with CFAs in the child.	Phenytoin	55-64	epoxide hydrolase 1	Homo sapiens	152-157	
19952982-9	2010	CONCLUSION: Maternal EPHX1 genotype may be associated with risk of fetal anomalies among pregnant women taking phenytoin.	Phenytoin	111-120	epoxide hydrolase 1	Homo sapiens	21-26	
19364907-1	2009	Microsomal epoxide hydrolase (EPHX1) biotransforms epoxide derivatives of pharmaceuticals, including metabolites of certain antiepileptic medications, such as phenytoin and carbamazepine, and many environmental epoxides, such as those derived from butadiene, benzene, and carcinogenic polyaromatic hydrocarbons.	Phenytoin	159-168	epoxide hydrolase 1	Homo sapiens	30-35	
11471167-6	2001	Recent studies suggest an association between the EPHX1 codon 113 polymorphism or homozygous null GSTM1 allele and the risk of carcinogenesis, emphysema, phenytoin-associated oral clefting, and the risk of spontaneous abortion.	Phenytoin	154-163	epoxide hydrolase 1	Homo sapiens	50-55	
28820457-0	2017	Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects.	Phenytoin	72-81	epoxide hydrolase 1	Homo sapiens	28-32	
9406998-1	1997	Human microsomal epoxide hydrolase (HYL1) plays an important role in the detoxification of environmental compounds and drugs, such as the aromatic anticonvulsants phenytoin, carbamazepine, and phenobarbital, by converting their P450-generated epoxide metabolites into nontoxic diols.	Phenytoin	163-172	epoxide hydrolase 1	Homo sapiens	6-34	
1683079-5	1991	Recent work elucidating differences in isoenzyme forms of cytochrome P-450 enzyme systems, glutathione, and microsomal epoxide hydrolase has provided increased interest in the multiple individual pharmacogenetic differences that may be significant factors affecting increased susceptibility to birth defects in individuals and families with fetal exposure to phenytoin.	Phenytoin	359-368	epoxide hydrolase 1	Homo sapiens	108-136